Blocking the Tim-3 pathway in MM models enhances NK cell degranulation and cytotoxic activity against MM cell lines and primary MM cells while simultaneously promoting up-regulation of effector molecules, including perforin and granzyme B. Studies have confirmed that Tim-3 blockade therapy significantly extends survival in MM patients [167]. This evidence concerns the gene PRF1 and Miyoshi myopathy.